Vaxcyte Inc
PCVX33.170USD
+0.150+0.45%
交易中 （美東）報價延遲15分鐘
4.28B總市值
虧損本益比TTM
關於 Vaxcyte Inc 公司
Vaxcyte Inc. 是一家臨牀階段疫苗公司。該公司致力於開發廣譜結合疫苗和蛋白質疫苗，以預防或治療細菌性傳染病。其主要候選疫苗 VAX-24 是一種已進入 III 期臨牀試驗的 24 價載體保留型肺炎球菌結合疫苗 (PCV)，正在開發用於預防侵襲性肺炎球菌疾病 (IPD)。VAX-31 是該公司的下一代 31 價 PCV，用於預防成人 IPD。其產品線還包括 VAX-A1、VAX-PG 和 VAX-GI。VAX-A1 是一種新型結合疫苗候選疫苗，旨在預防由 A 組鏈球菌 (Group A Strep) 引起的疾病。VAX-PG 是一種新型蛋白質疫苗候選疫苗，針對導致牙周炎（一種慢性口腔炎症疾病）的病原體。VAX-GI 是一種新型臨牀前疫苗候選疫苗，正在開發用於預防痢疾和志賀氏菌病。其技術平臺包括先進的化學和XpressCF無細胞蛋白質合成平臺。
公司簡介
公司代碼PCVX
公司名稱Vaxcyte Inc
上市日期Jun 12, 2020
CEOMr. Grant E. Pickering
員工數量414
證券類型Ordinary Share
年結日Jun 12
公司地址825 Industrial Road, Ste. 300
城市SAN CARLOS
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94070
電話16508370111
網址https://vaxcyte.com/
公司代碼PCVX
上市日期Jun 12, 2020
CEOMr. Grant E. Pickering
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
676.65K
+3.13%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
83.56K
+6.06%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
34.31K
+21.13%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-28.82%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+54.06%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+54.06%
Mr. Jacks Lee
Mr. Jacks Lee
Independent Director
Independent Director
3.04K
--
Mr. John P. Furey
Mr. John P. Furey
Independent Director
Independent Director
3.04K
--
Dr. Olivier Brandicourt
Dr. Olivier Brandicourt
Independent Director
Independent Director
1.15K
--
Dr. Heath Lukatch, Ph.D.
Dr. Heath Lukatch, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
676.65K
+3.13%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
83.56K
+6.06%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
34.31K
+21.13%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-28.82%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+54.06%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+54.06%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月2日 週六
更新時間: 8月2日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Janus Henderson Investors
11.27%
RA Capital Management, LP
9.45%
The Vanguard Group, Inc.
9.32%
Fidelity Management & Research Company LLC
8.31%
BlackRock Institutional Trust Company, N.A.
7.08%
Other
54.57%
持股股東
持股股東
佔比
Janus Henderson Investors
11.27%
RA Capital Management, LP
9.45%
The Vanguard Group, Inc.
9.32%
Fidelity Management & Research Company LLC
8.31%
BlackRock Institutional Trust Company, N.A.
7.08%
Other
54.57%
股東類型
持股股東
佔比
Investment Advisor
47.62%
Investment Advisor/Hedge Fund
40.88%
Hedge Fund
12.35%
Venture Capital
10.72%
Research Firm
1.95%
Private Equity
0.97%
Sovereign Wealth Fund
0.85%
Bank and Trust
0.73%
Individual Investor
0.70%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
652
151.34M
117.31%
-374.47K
2025Q1
669
149.26M
115.73%
-5.52M
2024Q4
629
143.44M
111.44%
-3.61M
2024Q3
579
138.80M
114.99%
+5.28M
2024Q2
508
125.57M
113.86%
-5.08M
2024Q1
487
122.06M
113.01%
+8.05M
2023Q4
444
106.09M
111.72%
-6.02M
2023Q3
417
110.70M
121.97%
-7.51M
2023Q2
397
109.13M
122.07%
+11.09M
2023Q1
366
92.70M
119.26%
-1.36M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Janus Henderson Investors
14.54M
11.27%
+2.77M
+23.58%
Apr 30, 2025
RA Capital Management, LP
12.19M
9.45%
+3.50M
+40.28%
Mar 31, 2025
The Vanguard Group, Inc.
12.02M
9.32%
+82.12K
+0.69%
Mar 31, 2025
Fidelity Management & Research Company LLC
10.73M
8.31%
-632.25K
-5.57%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.13M
7.08%
-112.81K
-1.22%
Mar 31, 2025
Wellington Management Company, LLP
6.42M
4.97%
+1.97M
+44.39%
Mar 31, 2025
Capital Research Global Investors
6.11M
4.74%
-100.42K
-1.62%
Mar 31, 2025
State Street Global Advisors (US)
4.41M
3.42%
-131.72K
-2.90%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.44M
2.66%
-429.53K
-11.11%
Mar 31, 2025
Kynam Capital Management LP
3.20M
2.48%
+863.20K
+36.94%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ALPS Medical Breakthroughs ETF
2.84%
Harbor Health Care ETF
2.75%
SPDR S&P Biotech ETF
1.36%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
Direxion Daily S&P Biotech Bull 3X Shares
0.77%
Invesco Nasdaq Biotechnology ETF
0.47%
ProShares Ultra Nasdaq Biotechnology
0.47%
iShares Biotechnology ETF
0.42%
Nuveen ESG Small-Cap ETF
0.36%
JPMorgan Fundamental Data Science Small Core ETF
0.36%
查看更多
ALPS Medical Breakthroughs ETF
佔比2.84%
Harbor Health Care ETF
佔比2.75%
SPDR S&P Biotech ETF
佔比1.36%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.85%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.77%
Invesco Nasdaq Biotechnology ETF
佔比0.47%
ProShares Ultra Nasdaq Biotechnology
佔比0.47%
iShares Biotechnology ETF
佔比0.42%
Nuveen ESG Small-Cap ETF
佔比0.36%
JPMorgan Fundamental Data Science Small Core ETF
佔比0.36%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
